@article {Neelapue001235, author = {Sattva S Neelapu and Sherry Adkins and Stephen M Ansell and Joshua Brody and Mitchell S Cairo and Jonathan W Friedberg and Justin P Kline and Ronald Levy and David L Porter and Koen van Besien and Michael Werner and Michael R Bishop}, title = {Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma}, volume = {8}, number = {2}, elocation-id = {e001235}, year = {2020}, doi = {10.1136/jitc-2020-001235}, publisher = {BMJ Specialist Journals}, abstract = {The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups. The rapid introduction of immunotherapeutic agents into the clinic, however, has presented significant questions regarding optimal treatment scheduling around existing chemotherapy/radiation options, as well as a need for improved understanding of how to properly manage patients and recognize toxicities. To address these challenges, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in lymphoma to develop a clinical practice guideline for the education of healthcare professionals on various aspects of immunotherapeutic treatment. The panel discussed subjects including treatment scheduling, immune-related adverse events (irAEs), and the integration of immunotherapy and stem cell transplant to form recommendations to guide healthcare professionals treating patients with lymphoma.}, URL = {https://jitc.bmj.com/content/8/2/e001235}, eprint = {https://jitc.bmj.com/content/8/2/e001235.full.pdf}, journal = {Journal for ImmunoTherapy of Cancer} }